Pathogen inactivation of platelets using ultraviolet C light: Effect on in vitro function and recovery and survival of platelets

Transfusion

Volumn 53, Issue 5, 2013, Pages 990-1000

  Bashir, Saber ^b   Cookson, Philip ^b   Wiltshire, Michael ^b   Hawkins, Louise ^b   Sonoda, Luke ^b   Thomas, Stephen ^b   Seltsam, Axel ^b   Tolksdorf, Frank ^b   Williamson, Lorna M ^b   Cardigan, Rebecca ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA3 INTEGRIN; CASPASE 3; CASPASE 7; CD63 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN IB ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; LIPOCORTIN 5; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD BUFFY COAT; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MITOCHONDRIAL MEMBRANE POTENTIAL; NORMAL HUMAN; PH; PLATELET MICROPARTICLE; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; ULTRAVIOLET C RADIATION;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD SAFETY; CELL SURVIVAL; HUMANS; HYDROGEN-ION CONCENTRATION; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; ULTRAVIOLET RAYS;

EID: 84877722179     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03854.x     Document Type: Article

References (46)

1. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasonglès P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Prowse C, et al,. Pathogen inactivation of platelet concentrates. Vox Sang 2010; 99: 85-95.
2. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L,. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79: 206-14.
3. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-92.
4. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG,. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet a light. Transfusion 2004; 44: 1732-40.
5. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
6. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L,; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
7. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-41.
8. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ,; Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
9. Lozano M, Knutson F, Tardivel R, Cid J, Maymõ RM, Löf H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C,. A multi-centre study of therapeutic efficacy and safety of platelet component treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7d prior to transfusion. Br J Haematol 2011; 153: 393-401.
10. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
11. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Müller TH, Völker U,. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49: 2612-24.
12. Mohr H, Gravemann U, Bayer A, Müller TH,. Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 49: 1956-63.
13. Calkins J, Wheeler JS, Keller CI, Colley E, Hazle JD,. Comparative ultraviolet action spectra (254-320 nm) of five "wild-type" eukaryotic microorganisms and Escherichia coli. Radiat Res 1988; 114: 307-18.
14. Kallenbach NR, Cornelius PA, Negus D, Montgomerie D, Englander S,. Inactivation of viruses by ultraviolet light. Curr Stud Hematol Blood Transfus 1989;(56): 70-82.
15. Irsch J, Lin L,. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system™. Transfus Med Hemother 2011; 38: 19-31.
16. Seltsam A, Muller TH,. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
17. Marschner S, Goodrich R,. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
18. Bertolini F, Murphy S,. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Transfusion 1996; 36: 128-32.
19. VandenBroeke T, Dumont LJ, Hunter S, Nixon J, Murphy S, Roger J, Herschel L, AuBuchon JP, Gulliksson H, Dengler T, Hornsey V, Prowse C,; Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Platelet storage solution affects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. Vox Sang 2004; 86: 183-8.
20. Turner CP, Sutherland J, Wadhwa M, Dilger P, Cardigan R,. In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools. Vox Sang 2005; 88: 164-71.
21. Cookson P, Sutherland J, Turner C, Bashir S, Wiltshire M, Hancock V, Smith K, Cardigan R,. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010; 20: 392-402.
22. Murphy S,. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004; 44: 131-3.
23. FDA. Blood Products Advisory Committee Mar 13-14. 2003. [cited 5 May 2011]. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/ 3940t1.htm and http://www.fda.gov/ohrma/dockets/ac/03/transcripts/3940t2.htm
24. Terpstra FG, van't Wout AB, Schuitemaker H, van Engelenburg FA, Dekkers DW, Verhaar R, de Korte D, Verhoeven AJ,. Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. Transfusion 2008; 48: 304-13.
25. Janetzko K, Hinz K, Marschner S, Goodrich R, Klüter H,. Evaluation of differernt preparation procedures of pathogen reduction technology (Mirasol)-treated platelets collected by plateletpheresis. Transfus Med Hemother 2009; 36: 309-15.
26. Holme S,. Storage and quality assessment of platelets. Vox Sang 1998; 74 (Suppl 2): 207-16.
27. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Högman CF,. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000; 78: 209-16.
28. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP,. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-6.
29. Sandgren P, Tolksdorf F, Struff WG, Gulliksson H,. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method. Vox Sang 2011; 101: 35-43.
30. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
31. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
32. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L,. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496-504.
33. Verhaar R, Dekkers DW, De Cuyper IM, Ginsberg MH, de Korte D, Verhoeven AJ,. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112: 4935-9.
34. Seltsam A, Muller TH,. UVC Irradiation for pathogen reduction of platelets concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
35. Javela K, Eronen J, Sarna S, Kekomäki R,. Soluble glycoprotein V as a quality marker of platelet concentrates stressed by transportation. Transfusion 2005; 45: 1504-11.
36. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, Jones MK, Christoffel T, Pellham E, Bailey SL, Slichter SJ,; BEST Collaborative. A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day-stored PLT-rich plasma and buffy coat PLTs from the same subjects. Transfusion 2011; 51: 1241-8.
37. Slichter SJ, Bolgiano D, Jones MK, Christoffel T, Corson J, Rose L, Foley J, Popovsky M, Baril LL, Corda T, Dincecco DM, Snyder EL,. Viability and function of 8-day-stored apheresis platelets. Transfusion 2006; 46: 1763-9.
38. Slichter SJ, Bolgiano D, Corson J, Jones MK, Christoffel T,. Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte. Transfusion 2010; 50: 2199-209.
39. Murphy S,. The case for a new approach for documenting platelet viability. Transfusion 2006; 46: 49S-52S.
40. AuBuchon JP, Herschel L, Roger J,. Further evaluation of a new standard of efficacy for stored platelets. Transfusion 2005; 45: 1143-50.
41. Keegan T, Heaton A, Holme S, Owens M, Nelson E, Carmen R,. Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr. Transfusion 1992; 32: 113-20.
42. Leytin V, Allen DJ, Gwozdz A, Garvey B, Freedman J,. Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates. Transfusion 2004; 44: 1487-95.
43. Perrotta PL, Perrotta CL, Snyder EL,. Apoptotic activity in stored human platelets. Transfusion 2003; 43: 526-35.
44. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS,. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991; 31: 409-14.
45. Holme S, Sweeney JD, Sawyer S, Elfath MD,. The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 37: 12-7.
46. Dumont LJ, AuBuchon JP, Whitley P, Herschel LH, Johnson A, McNeil D, Sawyer S, Roger JC,. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002; 42: 847-54.